Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis

Hepatology

Volumn 44, Issue 6, 2006, Pages 1528-1534

  Primignani, Massimo ^a   Barosi, Giovanni ^b   Bergamaschi, Gaetano ^b   Gianelli, Umberto ^a   Fabris, Federica ^a   Reati, Raffaella ^a   Dell'Era, Alessandra ^a   Bucciarelli, Paolo ^a   Mannucci, Pier Mannuccio ^a,c  

^a UNIVERSITY OF MILAN   (Italy)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^c University of Milan ^*  (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE 2;

ADULT; AGED; ARTICLE; BONE MARROW BIOPSY; BUDD CHIARI SYNDROME; CLONAL VARIATION; EXTRAHEPATIC BILE DUCT OBSTRUCTION; FEMALE; GENE MUTATION; HEMATOLOGICAL PARAMETERS; HEMATOPOIESIS; HUMAN; KIDNEY VEIN THROMBOSIS; MAJOR CLINICAL STUDY; MALE; MYELOPROLIFERATIVE DISORDER; PREDICTIVE VALIDITY; PRIORITY JOURNAL; RISK FACTOR; SENSITIVITY ANALYSIS; THROMBOPHILIA; X CHROMOSOME;

ADOLESCENT; ADULT; AGED; BIOPSY; BONE MARROW; CHILD; CONSTRICTION, PATHOLOGIC; FEMALE; HEPATIC VEIN THROMBOSIS; HUMANS; HYPERTENSION, PORTAL; JANUS KINASE 2; MALE; MIDDLE AGED; MUTATION; MYELOPROLIFERATIVE DISORDERS; PORTAL VEIN; RETROSPECTIVE STUDIES; SPLANCHNIC CIRCULATION; VENOUS THROMBOSIS;

EID: 33845630695     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.21435     Document Type: Article

References (29)

1. Denninger MH, Chait Y, Casedevall N, Hillaire S, Guillin MC, Bezeaud A, et al. Cause of portal or hepatic venous thrombosis in adults: the role of multiple concurrent factors. HEPATOLOGY 2000;31:587-591.
2. Amitrano L, Guardascione MA, Ames PR, Margaglione M, Antinolfi I, Iannaccone L, et al. Thrombophilic genotypes, natural anticoagulants, and plasma homocysteine in myeloproliferative disorders: relationship with splanchnic vein thrombosis and arterial disease. Am J Hematol 2003;72:75-81.
3. Primignani M, Martinelli I, Bucciarelli P, Battaglioli T, Reati R, Fabrís F, et al. Risk factors for thrombophilia in extrahepatic portal vein obstruction. HEPATOLOGY 2005;41:603-608.
4. De Stefano V, Teofili L, Leone G, Michiels JJ. Spontaneous erythroid colony formation as the clue to an underlying myeloproliferative disorder in patients with Budd-Chiari syndrome or portal vein thrombosis. Semin Thromb Hemost 1997;23:411-418.
5. Gruppo Italiano Studio Policitemia. Polycythemia vera: the natural history of 1213 patients followed for 20 years. Ann Intern Med 1995;123:656-664.
6. Chait Y, Condat B, Cazals-Hatem D, Rufat P, Atmani S, Chaoui D, et al. Relevance of the criteria commonly used to diagnose myeloproliferative disorder in patients with splanchnic vein thrombosis. Br J Haematol 2005; 129:553-560.
7. Barosi G, Buratti A, Costa A, Liberato LN, Balduini C, Cazzola M, et al. An atypical myeloproliferative disorder with high thrombotic risk and slow disease progression. Cancer 1991;68:2310-2318.
8. Dudley JM, Westwood N, Leonard S, Eridani S, Pearson TC. Primary polycythemia: positive diagnosis using the differential response of primitive and mature erithroid progenitors to erythropoietin, interleukin3 and alfa-interferon. Br J Hematol 1990;75:188-194.
9. Masters GS, Baines P, Jacobs A. Erythroid colony growth from peripheral blood and bone marrow in polycythaemia. J Clin Pathol 1990;43:937-941.
10. Liu E, Jelinek J, Pastore YD, Guan Y, Prchal JF, Prchal JT. Discrimination of polycythemias and thrombocytoses by novel, simple, accurate clonality assays and comparison with PRV-1 expression and BFU-E response to erythropoetin. Blood 2003;101:3294-3301.
11. Moliterno AR, Hankins WD, Spivak JL. Impaired expression of the thrombopoietin receptor by platelets from patients with polycythemia vera. N Engl J Med 1998;338:572-580.
12. Klippel S, Strunck E, Temerinac S, Bench AJ, Meinhardt G, Mohr U, et al. Quantification of PRV-1 mRNA distinguishes polycythemia vera from secondary erythrocytosis. Blood 2003;102:3569-3574.
13. Kralovics R, Buser AS, Teo SS, Coers J, Tichelli A, van der Maas AP, et al. Comparison of molecular markers in a cohort of patients with chronic myeloproliferative disorders. Blood 2003;102:1869-1971.
14. Chiusolo P, La Barbera EO, Laurenti L, Piccirillo N, Sora F, Giordano G, et al. Clonal hemopoiesis and risk of thrombosis in young female patients with essential thrombocythemia. Exp Hematol 2001;29:670-676.
15. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005;434:1144-1148.
16. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005;352:1779-1790.
17. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, et al. Cancer Genome Project. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005;365:1054-1061.
18. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005;7:387-397.
19. Zhao R, Xing S, Li Z, Fu X, Li Q, Krantz SB, et al. Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem 2005;280:22788-22792.
20. Jones AV, Kreil S, Zoi K, Waghorn K, Curtis C, Zhang L, et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 2005;106:2162-2168.
21. Steensma DP, Dewald GW, Lasho TL, Powell HL, McClure RF, Levine RL, et al. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes. Blood 2005;106:1207-1209.
22. Jelinek J, Oki Y, Gharibyan V, Bueso-Ramos C, Prchal JT, Verstovsek S, et al. JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. Blood 2005;106:3370-3373.
23. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002;100:2292-2302.
24. Thiele J, Kvasnicka HM, Facchetti F, Franco V, van der Walt J, Orazi A. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica 2005;90:1128-1132.
25. Tonon L, Bergamaschi G, Dellavecchia C, Rosti V, Lucotti C, Malabarba L, et al. Unbalanced X-chromosome inactivation in haemopoietic cells from normal women. Br J Haematol 1998;102:996-1003.
26. Hadgu A, Dendukuri N, Hilden J. Evaluation of nucleic acid amplification tests in the absence of a perfect gold-standard test: a review of the statistical and epidemiologic issues. Epidemiology 2005;16:604-612.
27. Tefferi A, Gilliland DG. The JAK2V617F tyrosine kinase mutation in myeloproliferative disorders: status report and immediate implications for disease classification and diagnosis. Mayo Clin Proc 2005;80:947-958.
28. Patel RK, Lea NC, Heneghan MA, Westwood NB, Milojkovic D, Thanigaikumar M, et al. Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome. Gastroenterology 2006;130:2031-2038.
29. Miller WC. Bias in discrepant analysis: when two wrongs don't make it a right. J Clin Epidemiol 1998;51:219-231.